El interés en corto de TEN Holdings da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de TEN Holdings. Los datos de interés en corto se actualizan cada dos semanas.

TEN Holdings (NASDAQ:XHLD) Bolsa, Informe de interés en corto

TEN Holdings

TEN Holdings Inc is a provider of event planning, production, and broadcasting services. The company produces virtual and hybrid events and physical events. Virtual and hybrid events involve virtual and hybrid event planning, production and broadcasting services, and continuing education services, all of which are supported by its Xyvid Pro Platform. Physical events involve live streaming and video recording of physical events. The Company operates business as one operating segment which includes two revenue types: Hybrid and Virtual Events and Physical Events.

Stock,Market,Graph,Trading,Analysis,Investment,Financial,,Stock,Exchange,Financial

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ABSI

ALLT

ALUR

ASNS

AXDX

DBVT

DEVS

FNGR

GRAL

LRHC

LUCY

PLRZ

UBER

WBUY

XHLD

XTKG

Las acciones de Everus Construction Group suben un 14,7 % tras superar expectativas de ganancias y ventas en el primer trimestre.

Acciones de Everus Construction (ECG) se disparan un 15%; Aquí están 20 acciones que se mueven en premercado

Movimiento de acciones

Intraday Update

AUID

BHAT

BNTC

GCTK

INNV

MCVT

OUST

PNBK

PSTV

RVSB

TNMG

USAR

Ouster sorprende con resultados mejores de lo esperado y sus acciones suben un 8,95%. Descubre las acciones que dominan el premercado.

Las acciones de Ouster (OUST) suben un 9%; Aquí están 20 acciones que se mueven en el premercado de EE.UU.

WIIM

IART

Integra LifeSciences shares are trading higher after the company reported better-than-expected Q2 financial results,

Oppenheimer analyst Ittai Kidron maintains Confluent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFLT#NASDAQ">CFLT</a>) with a Outperform and lowers the price target from $32 to $26.

Price Target

Analyst Ratings

CFLT

Oppenheimer Maintains Outperform on Confluent, Lowers Price Target to $26

CLMB

Climb Global Solutions shares are trading higher after the company reported better-than-expected Q2 financial results.

TROX

Tronox Holdings shares are trading lower after the company reported worse-than-expected Q2 financial results and narrowed its FY25 sales guidance.

Oppenheimer analyst Jason Helfstein maintains Compass (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COMP#NYSE">COMP</a>) with a Outperform and raises the price target from $10 to $11.

COMP

Oppenheimer Maintains Outperform on Compass, Raises Price Target to $11

GCL Global Holdings shares are trading higher after the company reported a year-over-year increase in FY25 revenue results.

Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYAI#NASDAQ">DYAI</a>), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced the pricing of its previously announced underwritten public offering of 6,052,000 shares of common stock at a public offering price of $0.95 per share. The Company expects the gross proceeds from this offering to be approximately $5.75 million, before deducting the underwriting discount and other offering expenses. Closing of the offering is expected to occur on August 1, 2025, subject to customary closing conditions.
Craig-Hallum Capital Group LLC is acting as the sole managing underwriter for the offering.
Dyadic intends to use the net proceeds from the offering for working capital and general corporate purposes, such as product development, sales and marketing.

Offerings

DYAI

Dyadic International Prices  $5.75M Public Offering Of 6.052M Shares Of Common Stock At $0.95/Share

Peabody Energy shares are trading lower after the company reported worse-than-expected Q2 financial results.

Oppenheimer analyst Noah Kaye maintains Clean Harbors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLH#NYSE">CLH</a>) with a Outperform and raises the price target from $254 to $256.

Oppenheimer Maintains Outperform on Clean Harbors, Raises Price Target to $256

OMCL

Omnicell shares are trading higher after the company reported better-than-expected Q2 financial results, issued Q3 sales guidance above estimates, and raised its FY25 guidance.

Oppenheimer analyst Michael Wiederhorn maintains Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) with a Outperform and lowers the price target from $650 to $580.

Oppenheimer Maintains Outperform on Chemed, Lowers Price Target to $580

MDXG

MiMedx Group shares are trading higher after the company reported better-than-expected Q2 financial results.

Rush Street Interactive shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY25 sales guidance. Also, Needham raised its price target on the stock from  $17 to $21.

SNDL

SNDL shares are trading higher after the company reported better-than-expected Q2 financial results.

PALI-2108 is the first and only PDE4 inhibitor designed to target terminal ileum and colon for fibrostenotic Crohn's disease (FSCD) and ulcerative colitis (UC), to address significant unmet medical needs Inflammatory Bowel Disease is a large and growing market opportunity in China, with forecasts approaching $1B in total revenues by 2030
Carlsbad, CA, July 31, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALI#NASDAQ">PALI</a>) ("Palisade," "Palisade Bio," or the "Company"), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that the China National Intellectual Property Administration has issued a Notice of Allowance for a patent covering PALI-2108, the Company's novel, locally-activated, terminal ileum and colon-targeted phosphodiesterase-4 B/D (PDE4 B/D) inhibitor being developed for fibrostenotic Crohn's disease (FSCD) and moderate to severe ulcerative colitis (UC).
Once issued, the allowed patent titled, "Gut Microbiota-Activated PDE4 Inhibitor Prodrug," will cover claims on the composition of matter for PALI-2108 in China with a base patent term currently extending into 2045, subject to extension to account for time required to fulfill requirements for regulatory approval.

Biotech

Global

General

PALI

Palisade Bio Secures China Patent For PALI-2108, A Targeted PDE4 Inhibitor For Crohn's Disease And Ulcerative Colitis

CVR Energy shares are trading lower following a Q2 adjusted EPS miss.

VCEL

Vericel shares are trading lower after the company reported a Q2 revenue miss.

WeRide shares are trading higher following the release of its Q2 financial results.

APLS

Apellis Pharmaceuticals shares are trading higher after the company reported a Q2 EPS beat.

CMCSA

During Conf Call, Comcast Says About Half Of Eligible New Customers Choosing 5-Year Price Guarantee In Q2

Earnings

Press Releases

TEN Holdings, Inc. Reports Full Year 2024 Financial Results

TEN Holdings, Inc. Announces Participation in the LD Micro Invitational XV

Entertainment

TEN Holdings' Subsidiary Delivers Scalable Solutions with Zero Downtime for a Big 4 Consulting Firm's Global Broadcasts

TEN Holdings Sponsors CancerCare® Spring Gala in Support of Critical Cancer Support Services

Small Cap

TEN Holdings Announces Participation in The D. Boral Capital Inaugural Global Conference

TEN Holdings Recognized as a "High Performer" and "Easy to Do Business With" in G2's Spring 2025 Reports

TEN Holdings Inc. Reports First Quarter 2025 Financial Results

TEN Holdings Announces Participation in Investor Conferences for June 2025

TEN Holdings Announces Early Adopter Program for New SaaS Product, Ten Events Pro

Comments

TEN Holdings

Interés en corto

TEN Holdings (NASDAQ:XHLD) Bolsa, Informe de interés en corto

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL